<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although allogeneic stem cell transplantation from a human leukocyte antigen (HLA)-identical related donor offers a potential cure for patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), a suitably matched related donor is unavailable for approximately two thirds of patients </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, umbilical cord blood from unrelated donors have been used as an alternative stem cell source for adult patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we updated the results of unrelated cord blood transplantation (CBT) after myeloablative conditioning for 22 adult patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Diagnosis at transplantation included <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) (n = 3), <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) (n = 2), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t (n = 2), and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-related secondary <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) (n = 15) </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were treated with total body irradiation (12 Gy), <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (Ara-C) and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> followed by unrelated HLA-mismatched CBT </plain></SENT>
<SENT sid="5" pm="."><plain>The median age was 40 years (range, 19 - 51 years), the median weight was 54.5 kg (range, 43 - 75 kg), and the median number of cryopreserved nucleated cells was 2.43 x 10(7)/kg (range, 1.82 - 4.10 x 10(7)/kg) </plain></SENT>
<SENT sid="6" pm="."><plain>Twenty one patients had myeloid reconstitution and the median time to more than 0.5 x 10(9)/l absolute neutrophil count was 22.5 days </plain></SENT>
<SENT sid="7" pm="."><plain>A self-sustained platelet count more than 50 x 10(9)/l was achieved in 19 patients at a median time of 49 days </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> GVHD above grade II occurred in seven of 21 evaluable patients and <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD in 16 of 19 evaluable patients </plain></SENT>
<SENT sid="9" pm="."><plain>Among 16 <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD patients, in eight patients the disease was extensive </plain></SENT>
<SENT sid="10" pm="."><plain>Seventeen patients are alive and free of disease at between 371 and 2562 days after transplantation </plain></SENT>
<SENT sid="11" pm="."><plain>With a median follow-up of 1505 days, the probability of disease-free survival at 4 years was 76.0% </plain></SENT>
<SENT sid="12" pm="."><plain>These results suggest that adult <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients without suitable related or unrelated bone marrow donors should be considered as candidates for CBT </plain></SENT>
</text></document>